Long‐term efficacy of SGLT2 inhibitors for elderly patients with acute decompensated heart failure: The OASIS‐HF study

Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) have been widely demonstrated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization, regardless of left ventricular ejection fraction (LVEF). However, data on the extent to which rehospitalization is suppressed follo...

Full description

Saved in:
Bibliographic Details
Published in:ESC Heart Failure Vol. 12; no. 1; pp. 447 - 455
Main Authors: Amioka, Michitaka, Kinoshita, Hiroki, Fuji, Yuto, Nitta, Kazuhiro, Yamane, Kenichi, Shokawa, Tomoki, Nakano, Yukiko
Format: Journal Article
Language:English
Published: England John Wiley & Sons, Inc 01.02.2025
John Wiley and Sons Inc
Wiley
Subjects:
Acute Disease
Aged
Aged, 80 and over
Beta blockers
Blood pressure
Cardiovascular death
Demographics
Diabetes
Diuretics
Ejection fraction
Female
Follow-Up Studies
Glomerular Filtration Rate
Heart failure
Heart Failure - drug therapy
Heart Failure - mortality
Heart Failure - physiopathology
Hospitalization
Humans
Male
Original
Patient Readmission - trends
Patients
Prospective Studies
Quality of life
Rehospitalization
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Sodium‐glucose cotransporter 2 inhibitors
Stroke Volume - physiology
Survival Rate - trends
Time Factors
Treatment Outcome
Variables
Ventricular Function, Left - physiology
Heart failure
Cardiovascular death
Rehospitalization
Sodium‐glucose cotransporter 2 inhibitors
Ejection fraction
ISSN:2055-5822, 2055-5822
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) have been widely demonstrated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization, regardless of left ventricular ejection fraction (LVEF). However, data on the extent to which rehospitalization is suppressed following HF hospitalization are limited. This study investigated the effects of SGLT2i on rehospitalization and cardiovascular death. Methods and results The OASIS‐HF study, a multicentre, prospective observational cohort study, enrolled 361 patients aged ≥75 years hospitalized for acute decompensated HF. The impact on composite events of HF rehospitalization or cardiovascular death and the number of annual rehospitalizations were evaluated between the conventional medical therapy and SGLT2i groups. The change in eGFR slope at the 1‐year mark after the initiation of treatment in both groups was also assessed. Over an average follow‐up period of 24.9 months, composite events occurred in 70 (35.4%) of the conventional therapy group and 36 (22.1%) of the SGLT2i group (log‐rank: P = 0.016). The average number of rehospitalizations for HF per year was 0.22 ± 0.13 vs. 0.14 ± 0.08, respectively (P = 0.019). The change in eGFR over 1 year was significantly slower in the SGLT2i group compared with the conventional group (−3.55 ± 8.46 vs. −1.42 ± 7.28 mL/min/1.73 m2, P = 0.025). Conclusions The SGLT2i are not only associated with the reduction of the composite events of HF rehospitalization or cardiovascular death and protect against worsening renal function but also with a decrease in long‐term repeated HF rehospitalizations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.15088